StockNews.com Upgrades VolitionRx (NYSE:VNRX) to Sell

StockNews.com upgraded shares of VolitionRx (NYSE:VNRX) to a sell rating in a research report report published on Wednesday morning.

Separately, Cantor Fitzgerald lowered their price objective on shares of VolitionRx from $3.00 to $2.00 and set an overweight rating for the company in a research report on Wednesday, August 16th.

VolitionRx Price Performance

VNRX opened at $1.22 on Wednesday. The stock has a market capitalization of $95.33 million, a PE ratio of -2.18 and a beta of 1.58. VolitionRx has a 1-year low of $1.12 and a 1-year high of $2.74. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.56.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.